<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gray, Richard G.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ATLAS: 10 versus 5 Years of Adjuvant Tamoxifen in ER-Positive Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with tamoxifen for 5 years has substantially reduced the risk of breast cancer recurrence and death throughout the first 15 years after diagnosis of estrogen receptor (ER)-positive early breast cancer [Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2011]. The Adjuvant Tamoxifen: Longer Against Shorter [ATLAS] trial compared the effects of continuing tamoxifen for a total of 10 years with stopping after the standard 5 years of treatment. This article presents data from the ATLAS trial on the effect of tamoxifen on 15-year survival [Davies C et al. Lancet 2012].</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>